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Abstract
Background: Modern radiotherapy offers various possibilities for image guided verification of patient positioning.
Different clinically relevant IGRT (image guided radiotherapy) scenarios were considered with regard to their
influence on dosimetric plan quality and normal tissue complication probability (NTCP).
Methods: This study is based on treatment plans of 50 prostate patients. We evaluate the clinically performed
IGRT and simulate the influence of different daily IGRT scenarios on plan quality. Imaging doses of planar and
cone-beam-CT (CBCT) images for three different energies (6 MV, 1 MV and 121 kV) were added to the treatment
plans. The plan quality of the different scenarios was assessed by a visual inspection of the dose distribution and
dose-volume-histogram (DVH) and a statistical analysis of DVH criteria. In addition, an assessment of the normal
tissue complication probability was performed.
Results: Daily 1MV-CBCTs result in undesirable high dose regions in the target volume. The DVH shows that the
scenarios with actual imaging performed, daily kV-CBCT and daily 6MV imaging (1x CBCT, 4x planar images per
week) do not differ exceedingly from the original plan; especially imaging with daily kV-CBCT has little influence
to the sparing of organs at risk. In contrast, daily 1MV- CBCT entails an additional dose of up to two fraction doses. Due
to the additional dose amount some DVH constraints for plan acceptability could no longer be satisfied, especially for
the daily 1MV-CBCT scenario. This scenario also shows increased NTCP for the rectum.
Conclusion: Daily kV-CBCT has negligible influence on plan quality and is commendable for the clinical routine.
If no kV-modality is available, a daily IGRT scenario with one CBCT per week and planar axial images on the other days
should be preferred over daily MV-CBCT.
Keywords: Imaging dose distribution, Linac-based imaging, IGRT, NTCP modelling, Kilovoltage imaging, Megavoltage
imaging, Prostate
Background
Modern radiotherapy achieves highly conformal dose
distributions even for complex-shaped target volumes,
combining tumour coverage and sparing of organs at
risk (OAR). The more precisely patient set-up can be
achieved and maintained between and within treatment
sessions, the more can safety margins be reduced and
OAR avoided [1–4]. To optimally achieve this, image-
guidance (IGRT) is a prerequisite, and it has been advo-
cated that daily imaging should be performed. However,
since most imaging techniques rely on ionizing radi-
ation, each verification image entails additional dose to
the patient.
The aim of this study is to assess in how far the plan
quality and the modelled NTCP endpoints considered in
treatment planning are affected by daily image-guidance
for one of the most frequent IGRT indications, prostate
cancer. Prostate radiotherapy is one of the main candi-
dates for daily imaging due to inter-and intra-fraction
mobility of the prostate and different filling levels of the
surrounding organs (bladder and rectum). At the same
time, the vicinity of these organs to the target volume* Correspondence: katharina.bell@uks.eu
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means that very high dose gradients are involved, so that
exact positioning must be verified [5–8].
A great number of different techniques are available
for pre-treatment patient set-up verification, most relying
on ionizing radiation, but differing in several respects:
linac-based vs. external, planar vs. 3D (cone-beam CT),
photon energy (kV or MV or some kind of intermediate
energy photon beam). Furthermore, there is yet no con-
sensus on whether daily imaging should be preferred over
frequent, but non-daily verification. We therefore consid-
ered a set of realistic and representative imaging scenarios
which are relevant to the clinical routine: Firstly, the
original plan without imaging dose, which is the “gold
standard” that was accepted for treatment (scenario 1).
Moreover, the realistic imaging scenario carried out at
our institution was included in the analysis as an example
of a realistic clinical setting, although this did not involve
daily, but 2–3 weekly imaging (scenario 2). On this basis,
three scenarios for daily IGRT were simulated: a) daily kV-
CBCT (cone-beam computed tomography) (scenario 3),
which is the preferred option since image quality is best,
while at the same time image dose is low [9]; b) daily IBL
(image beam line) CBCT (scenario 4). The IBL has been
marketed under the name kView, suggesting a kV-like en-
ergy spectrum, has a nominal energy of 1 MV and a carbon
target [10, 11]. Therefore, users who are not equipped with
“real” kV techniques may be tempted to use the IBL in-
stead in a similar manner. c) In clinics where only the
treatment beam (TBL) line is available for imaging, it is
well-known that the additional imaging dose adds up
considerably if daily CBCT are taken. We therefore
opted for a scenario with one weekly 6 MV-CBCT and
planar axial images on the other days (scenario 5).
Most studies so far have focussed on imaging dose by
itself and not the clinical consequences on plan quality
[12–17]. This is mainly indebted to the fact that imaging
energies are not usually commissioned in the treatment
planning system (TPS) and not included in the treat-
ment plan. A few studies have calculated the imaging
dose for each patient on the planning CT [17–21], but a
systematic evaluation of different imaging scenarios on
treatment plan quality is still missing. Furthermore,
biological effects have been generally disregarded. We
hence focussed on two aspects: firstly the dosimetric
plan quality of the summation plan (treatment plus
image guidance), including the dose distribution, dose-
volume histogram (DVH), and planning objectives, and
secondly the influence on normal-tissue complication
probability (NTCP). For NTCP we considered bio-
logical endpoints for the OARs: rectum, bladder and
femoral heads, in addition, regarding the rectum we
also analysed clinically relevant endpoints like rectal
bleeding and proctitis. To our knowledge, no such in-
vestigation is available in the literature.
Methods
Patient collective and treatment
This study is based on treatment plans of 50 prostate
cancer patients retrospectively selected for a previous
study [22], which analysed pre-treatment set-up images
to determine set-up deviations. For the present study,
the data from the previous study were used, with no fur-
ther interaction with the patients. Therefore, an approval
by the local ethics committee was not necessary due to
the retrospective nature of this evaluation, however an
approval of the institutional review board was obtained.
All patients received radiotherapy for two series. The
planning target volume (PTV) encompassed the prostate
(or the prostate bed after surgery), the seminal vesicles and
the surrounding tissue of the small pelvis. For the shrinking
field this was reduced in order to avoid high doses in the
rectum. A total dose of 75 Gy was prescribed (1.8-2 Gy
daily). All patients gave written informed consent for IGRT.
Our department is equipped with three Siemens
(Siemens Healthcare, Erlangen, Germany) linear accelera-
tors, two Artistes and one Oncor, with matched energies.
All of them can be operated in the 6MV photon mode,
one Artiste disposes of the flattening filter free 7MV
photon energy, the other Artiste and the Oncor can
additionally be operated in the 18MV photon mode.
Treatment planning was carried out on the basis of a
planning CT acquired with a Philips Brilliance BigBore
120 kV (Philips Healthcare, DA Best, Netherlands).
Depending on the patient anatomy and resulting target
coverage and dose to OAR, either a 3D-conformal tech-
nique with 18 MV photon beams or (more frequently)
IMRT with 6 MV was applied for the PTV. The shrinking
field was always planned as 6 MV IMRT. Planning was
performed in the Philips Pinnacle TPS V9.2 (Philips
Healthcare, DA Best, Netherlands), using the collapsed
cone algorithm and a 2 mm dose grid.
Imaging scenarios and dose calculation
All three imaging techniques considered here are available
at our institution: a TBL with 6 MV, the IBL of nominally
1 MV and a kV system using 70–140 kV, which uses
121 kV for prostate imaging (both axial planar images and
kV-CBCT). The kV-system is available only at one of our
Artistes, while both Artistes are equipped with the IBL
modality. TBL imaging is feasible with all three linear ac-
celerators. All three energies were dosimetrically charac-
terized and are commissioned in the TPS, so that imaging
dose distributions could be calculated for each patient.
The modelling of the image beam line was performed
using the Pinnacle automatic modelling routine presenting
a very stable inversion in relation to a starting spectrum
selection [23]. kV-CBCT modelling in the TPS required
the addition of photon energy deposition kernels for low
photon energies. After their inclusion, modelling the
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percent-depth-dose curve and beam profiles could be
carried out similarly to standard commissioning of the
treatment beam [24].
The imaging scenarios are listed in Table 1. The ori-
ginal plan does not include any imaging dose. Although
it would be desirable to include the imaging dose at the
time of treatment planning, this is usually not the case
in the clinical routine, so that we take this plan as the
“gold standard” on which the decision to accept a plan
for treatment is normally based.
Scenario 2 is the realistic case that was carried out at
our institution. As our department has three linear accel-
erators with matched energies and identical 160 MLC, the
choice where the patients should be treated is based on
the IGRT technique available at the machines. Only one
linac offers kV imaging, two IBL, and all the TBL. In
principle, prostate patients are preferentially assigned to
the machine with kV capability due to the better soft-
tissue contrast. However, due to maintenance or repair,
sometimes also the clinical schedule, patients are occa-
sionally shifted between the machines, so that different
combinations of kV, IBL and TBL images are taken. Im-
ages were taken approximately every other fraction, and
about every third image was a CBCT. A detailed descrip-
tion of the imaging scenario can be found in [22].
Scenario 3 considers daily kV CBCT with 360°. The
kVision system uses an auto-exposure technique based
on a pre-shot, so that mAs values depend on the patient
diameter. For the patient collective, mAs values ranged
between 439 mAs and 1548 mAs per kV-CBCT. For
each patient, the average mAs of all kV-CBCTs was used
in the simulation of daily kV-CBCT. For those patients
who did not receive kV-CBCT, the simulation used the
average mAs of all patients.
IBL-CBCT and TBL-CBCT as simulated in scenarios 4
and 5 were taken with a full gantry rotation and a user-
defined monitor setting of between 7 and 16 monitor units
(MU) depending on patient size. Similarly to scenario 3, for
each patient the average MU from the realistic imaging per-
formed were taken for the simulation; in cases where this
was not available the average over all patient MU settings
was applied. For the TBL-CBCTs the overall mean value
was 16 MU, for IBL-CBCT 15 MU and for kV-CBCT 779
mAs. Planar axial images were taken with gantry angles of
0° and 90° with 1 MU each.
Dosimetric plan quality evaluation
The plan quality of the different scenarios was assessed
by evaluating the dose distributions and different dose-
volume objectives. Table 4 lists DVH criteria applied
during planning and in plan acceptance.
In addition to a visual inspection of the dose distribu-
tion a statistical analysis was performed using a one-way
ANOVA with repeated measures. The different IGRT
scenarios were compaired pairwise with the Wilcoxon-
signed-rank test. Moreover, it was assessed how many
times the plans with IGRT failed the acceptance criteria
that were passed by the original plan (Scenario 1).
Normal tissue complication probability
For biological endpoints of the relevant OARs we used
the NTCP model implemented in the Pinnacle TPS










NTCPj: probability of causing normal tissue complica-
tion for organ j
M: number of voxels in the organ j
Pij: Tumor control probability in voxel i of organ j
sj: relative seriality of the organ j
Δvij: relative volume of a voxel i of the organ j
We additionally considered some relevant clinical rectal
toxicity endpoints (rectal bleeding grades 1 and 2, proctitis
grades 1 and 2, rectal bleeding grade 2 only and proctitis
grade 2 only). As parameters were only available for the
Lyman Kutcher Burman (LKB) model for these endpoints,
they were calculated in this model using parameter values
from Gulliford et al. [27] (Table 3). With the LKB model
NTCP for non-uniformly irradiated volumes is calculated











TD50ðvolumeÞ ¼ TD50 ⋅ volumen
n is the volume factor for the structure, TD50 is the
dose at 50% probability of complication for the structure.
m is the slope factor:
Table 1 Imaging scenarios
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5
Original plan Actual imaging performed (non-daily) Daily kV CBCT Daily IBL CBCT Daily imaging: 1xTBL CBCT, 4xTBL planar images per week





Dose is the maximum dose to the structure, volume is
the effective volume computed from the dose volume
histogram [28].
Results
Dosimetric evaluation of the plan quality
An example of the dose distributions for all scenarios is
shown in Fig. 1. Obviously, the additional imaging dose
does not compromise PTV coverage. However, the use
of a daily IBL-CBCT causes some undesirable high dose
regions. Although slight changes in the lower dose re-
gions can be discerned, these can be better interpreted
based on the DVH and plan acceptability criteria.
Figure 1 also shows one example DVH including all
scenarios. While the original plan without imaging nat-
urally has lowest dose, scenario 2, 3 and 5 do not differ
exceedingly from the original plan. Especially the real
IGRT and the daily kV-CBCT do not have great influ-
ence on the OAR. Contrarily, daily IBL-CBCT causes a
pronounced shift in the DVH with an additional dose of
up to two fraction doses (on occasions, over 4 Gy).
Due to the concomitant imaging dose the volumetric
percentage of the OAR receiving a particular dose in-
creases. Accordingly, some DVH constraints for plan ac-
ceptability may no longer be satisfied. Table 4 lists the
number of patients for which a given DVH objective was
exceeded for the different scenarios (but satisfied by the
original plan).
Nearly all DVH criteria passed by the original plan
were equally satisfied by the realistic IGRT and the
daily kV-CBCT scenarios. Only in few cases (0–3)
were the criteria no longer met after imaging dose was
included. Plan acceptability was hence not markedly
compromised by imaging.
In contrast, daily IBL-CBCT caused the DVH criteria
to be exceeded in a notable number of cases (up to 14
for the rectum V70Gy). Almost every DVH objective
was affected by this, some frequently.
Despite the even higher MV photon energy, the TBL
scenario improved plan acceptability in comparison
with daily IBL-CBCT because of the dose reduction by
replacing four 6 MV-CBCT by axial images. Some DVH
constraints were always or nearly always met even with
scenario 5 (rectum V50Gy, V40Gy, posterior rectal wall
V50 Gy, also bladder V50 Gy, V65 Gy, etc.). Rectum
V70Gy < 10% was exceeded for 9 patients; this was the
only objective to be exceeded for more than 4 patients.
Mean DVH metrics are given in Table 5. These values
confirm the findings above, with scenario 2 causing the
smallest effects on the plan quality, followed by scenario
3. Daily imaging with IBL-CBCT lead to a noticeable
increase in OAR dose, reflected in an increase (up to 5%)
in the volume of OAR receiving a given dose. The effects
of the 6 MV scenario were larger than scenarios 2 and 3,
but considerably smaller than scenario 4.
The statistical analysis in most cases resulted in highly
significant differences between the scenarios (for p-
values see Tables 7 and 8), especially for the comparisons
with the IBL-scenario. Only the real imaging scenario in
comparison to the kV-scenario was not significant for a
number of DVH constraints (V65Gy and V60Gy of the
bladder and V60Gy of the rectum).
Normal tissue complication probability
The dose–response-curves for the NTCP show a typ-
ical sigmoidal course. For the biological endpoints (ne-
crosis, stenosis, contracture – see Table 2) the NTCP
for all OARs is small (Fig. 2), which was expected
since the DVH objectives for planning (in addition to
following the ALARA principle) are explicitly chosen
in a way to avoid normal tissue toxicity. The only
organ with more than 1% NTCP is the rectum, so we
disregard the bladder and femoral heads and focus
below on the clinically more relevant endpoints for
rectal toxicity. Average values for all patients for the
different scenarios are given in Table 6. Rectal bleed-
ing and proctitis grades 1 and 2 show probabilities for
toxicities up to 40%. Considering only grade 2 toxic-
ities, NTCP values decrease down to 6–10% for rectal
bleeding and to 14–20% for proctitis. The differences
in NTCP between the scenarios 2, 3 and 5 are minor,
with less than 3% increase. However, the IBL-CBCT
scenario leads to increased NTCP by up to 6% in com-
parison with scenario 1.
Again the statistical analysis shows highly significant
differences between the scenarios, only scenario 2 vs.
3 is not significant for all NTCP endpoints (Tables 7
and 8).
Table 2 Parameter and endpoints for NTCP calculation
ROI D50 γ α/β s Endpoint
Bladder 80 Gy 3.0 3 Gy 0.18 Symptomatical contracture
Rectum 80 Gy 2.2 3 Gy 1.50 Necrosis/Stenosis
Posterior rectal wall 80 Gy 2.2 3 Gy 1.50 Necrosis/Stenosis
Femoral heads 65 Gy 2.7 3 Gy 1.00 Necrosis
Table 3 Parameters for the LKB model for rectal toxicities [27]
Enpoint (toxicity grades) TD50 (Gy) Slope m Volume factor n
Rectal bleeding (G1&2) 59.2 0.29 0.17
Proctitis (G1&2) 57.3 0.33 0.2
Rectal bleeding (G2) 68.9 0.16 0.18
Proctitis (G2) 68.3 0.22 0.17
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Discussion
Comparison with previous studies
Most of the current literature regarding imaging dose
has focussed on the additional dose itself for different
modalities, especially kV-imaging. Amer et al. [13] assessed
additional doses of kV-CBCT from the Elekta Synergy
X-Ray system. They measured imaging doses on various
locations in a Rando phantom and at patients’surfaces.
The weighted doses for their in-house CBCT protocol
were 1.6 mGy for the head, 6 mGy for the lung and
22 mGy for the pelvis.
Similar results can be found in Ariyaratne et al. [15]
with a nominal measured concomitant dose to the pel-
vis of 30 mGy per CBCT exposure and in Schneider et
al. [16] who concluded that most imaging methods, in-
cluding pelvis CBCT protocols add no more extra
dose to the patient than the therapy dose variations
between different treatment techniques (e.g., IMRT in
contrast to 3D conformal treatment).
Dzierma et al. [17] evaluated the imaging dose and
dose distribution for three different modalities. For the
kV modality the findings fit well with the literature men-
tioned above (kV-CBCT resulted in a dose of about
25 mGy for the prostate and 3–9 mGy for head and
neck cases). Moreover they showed for head and neck
an extra dose of 80 mGy for 6 MV CBCT and 34–62 mGy
for IBL CBCT. For the prostate the 6 MV CBCT result in
an imaging dose of 120–150 mGy and 80–110 mGy for
IBL CBCT.
The few other studies to be found that calculated
the imaging dose on the planning CT did not system-
atically evaluate different IGRT scenarios but focussed
Fig. 1 Example dose distribution and DVH of one patient for all scenarios
Table 4 DVH criteria for plan acceptability and number of patients with exceeded DVH objectives for the different scenarios
Organ Criteria Scenario 2 Scenario 3 Scenario 4 Scenario 5
Bladder V75Gy < 15% 0 0 10 3
V70Gy < 20% 1 3 7 4
V65Gy < 50% 2 2 3 2
V50Gy < 50% 0 0 2 1
Rectum V70Gy < 10% 0 2 14 9
V60Gy < 30% 0 0 7 2
V50Gy < 50% 0 0 0 0
V40Gy < 70% 0 0 1 0
V30Gy < 80% 1 1 2 1
Posterior rectal wall V50Gy < 15% 0 0 3 0
V40Gy < 30% 2 1 5 3
D2% < 60Gy 0 0 4 1
Femoral heads V50Gy < 5% le 1 2 7 4
V50Gy < 5% ri 2 2 9 3
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on kV modalities [18–21]. Alaei et al. [20] showed that
the dose from daily kV CBCT results in an additional
isocenter dose of the order of 30–40 mGy for 35
fractions head and neck and 230–240 mGy for 25 frac-
tions pelvis irradiation. The authors used the commis-
sioning of kV CBCT beams in the TPS primarily to
include the imaging dose in the treatment plan prior
to optimization.
Overall, this study is the first to systematically analyse
the influence of different imaging scenarios on treatment
plan quality with respect to changing DVH constraints
and biological/clinical endpoints.
Fig. 2 Dose–response curves for NTCP
Table 6 Mean values ± standard deviations and lower - upper 95% confidence levels of the NTCP-analysis for the different scenarios
Organ Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5
Necrosis [%] 2.24 ± 0.21 (1.81-2.67) 2.46 ± 0.21 (2.03-2.89) 2.52 ± 0.23 (2.06-2.98) 3.86 ± 0.32 (3.22-4.50) 2.88 ± 0.25 (2.37-3.38)
Rectal bleeding
(G1&2) [%]
34.02 ± 1.02 (31.98-36.06) 35.08 ± 1.01 (33.04-37.12) 35.2 ± 1.04 (33.11-37.29) 39.98 ± 1.12 (37.74-42.22) 36.46 ± 1.05 (34.35-38.57)
Proctitis
(G1&2) [%]
35.88 ± 0.98 (33.91-37.85) 36.88 ± 0.98 (34.91-38.85) 36.98 ± 1.00 (34.96-39.00) 41.34 ± 1.06 (39.21-43.47) 38.12 ± 1.02 (36.08-40.16)
Rectal bleeding
(G2) [%]
6.48 ± 0.54 (5.40-7.56) 7.06 ± 0.55 (5.95-8.17) 7.2 ± 0.58 (6.06-8.37) 10.22 ± 0.78 (8.66-11.78) 7.86 ± 0.63 (6.60-9.12)
Proctitis (G2) [%] 14.5 ± 0.7 (13.09-15.91) 15.28 ± 0.73 (13.82-16.74) 15.3 ± 0.74 (13.81-16.79) 19.02 ± 0.89 (17.24-20.80) 16.22 ± 0.78 (14.65-17.79)
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Discussion of normal tissue complication probability
The NTCP calculations were performed with the bio-
logical response panel implemented in the Pinnacle TPS
using information of the Källmann S-model with appro-
priate endpoints for the relevant OARs (Table 2). As it is
the aim of every treatment plan to avoid normal tissue
toxicities, the endpoints like necrosis and stenosis show
probabilities of about 0% for most cases and OARs –
this is natural since the DVH constraints required for
plan acceptability in our institution rely on the clinical
information from the QUANTEC studies. Only the rec-
tum showed NTCP values of more than 1%, which is
why only this OAR was followed further. For the rectum,
different clinically interesting endpoints were consid-
ered. The incidence of late gastrointestinal toxicity after
prostate cancer treatment is a widely studied complica-
tion. Side effects like rectal bleeding or proctitis are no
uncommon complications. To take these clinical toxic-
ities into account many studies deal with the calculation
of NTCP parameters for specific rectal complications
[27, 29–31]. Gulliford et al. [27] estimated parameters
for the Lyman-Kutcher-Burman model for different rec-
tal complications of different grades observed in clinical
practice. As rectal bleeding is the most frequently re-
ported rectal toxicity, we assessed in our study the influ-
ence of the different IGRT scenarios on this toxicity,
moreover we chose proctitis as a second important rec-
tal complication. The Pinnacle TPS offers the possibility
Table 7 p-values of the statistical analysis, lower bound for the
ANOVA and Wilk’s Lambda for the multivariate tests



















Femoral heads V50Gy le <0.001 0.0040
V50Gy ri 0.0035 0.0084
Necrosis <0.001 <0.001
NTCP Rectal bleeding (G1&2) <0.001 <0.001
Proctitis (G1&2) <0.001 <0.001
Rectal bleeding (G2) <0.001 <0.001
Proctitis (G2) <0.001 <0.001
Table 8 p-values of the pair-wise Wilcoxon signed rank tests
Organ Criteria Scenario 2 vs. 3 Scenario 2 vs. 4 Scenario 2 vs. 5 Scenario 3 vs. 4 Scenario 3 vs. 5 Scenario 4 vs. 5
Bladder V75Gy 0.004 <0.001 <0.001 <0.001 <0.001 <0.001
V70Gy 0.0065 <0.001 <0.001 <0.001 <0.001 <0.001
V65Gy n.s. <0.001 <0.001 <0.001 <0.001 <0.001
V50Gy n.s. <0.001 <0.001 <0.001 <0.001 <0.001
Rectum V70Gy 0.0029 <0.001 <0.001 <0.001 <0.001 <0.001
V60Gy n.s. <0.001 <0.001 <0.001 <0.001 <0.001
V50Gy 0.020 <0.001 <0.001 <0.001 <0.001 <0.001
V40Gy 0.021 <0.001 <0.001 <0.001 <0.001 <0.001
V30Gy 0.003 <0.001 <0.001 <0.001 <0.001 <0.001
Posterior rectal wall V50Gy 0.003 <0.001 <0.001 <0.001 <0.001 <0.001
V40Gy 0.024 <0.001 <0.001 <0.001 <0.001 <0.001
D2% 0.050 <0.001 <0.001 <0.001 <0.001 <0.001
Femoral heads V50Gy le 0.021 <0.001 <0.001 <0.001 <0.001 <0.001
V50Gy ri 0.010 <0.001 <0.001 <0.001 0.001 <0.001
Necrosis n.s. <0.001 <0.001 <0.001 <0.001 <0.001
NTCP Rectal bleeding (G1&2) n.s. <0.001 <0.001 <0.001 <0.001 <0.001
Proctitis (G1&2) n.s. <0.001 <0.001 <0.001 <0.001 <0.001
Rectal bleeding (G2) n.s. <0.001 <0.001 <0.001 <0.001 <0.001
Proctitis (G2) n.s. <0.001 <0.001 <0.001 <0.001 <0.001
(n.s. not significant)
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to obtain NTCP response values for a ROI using the
Lyman-Kutcher-Burman model. With the parameters
“Dose at 50% probability”, “slope factor” and “volume
factor”, NTCP calculations for all organs and endpoints
could be performed. Using the results of Gulliford et al.
(Table 3) we estimated NTCP for the different imaging
scenarios regarding rectal bleeding and proctitis grades 1
and 2 and rectal bleeding and proctitis grade 2 only to
evaluate clinical consequences of the concomitant im-
aging dose. The use of two different NTCP models was
necessary since the overall OAR complication parameters
were only available for the Källmann-S-model, whereas the
model parameters for the rectum clinical endpoints could
only be found for the Lyman-Kutcher-Burman model.
Practical implications of the results
We have considered different realistic and clinically rele-
vant IGRT scenarios: Scenario 1 considers the original plan
representing the planned and accepted case for treatment.
This scenario provides a reference to evaluate the scenarios
including imaging doses.
At our institution the frequency and technique of the
setup images differ for each patient due to shifting
between three machines with matched energies but
different imaging modalities. Therefore, imaging dose
is not a-priori included in the treatment plan. This is
acceptable since extensive previous tests have shown
that the realistic imaging dose accumulated shows
only minimal effects on plan quality. This is demon-
strated again in scenario 2, which reflects the actual
IGRT received by each patient. While this involved
non-daily imaging, it shows only minimal effects on
the plan quality; the majority of plans remains within
the acceptance criteria and the additional dose contri-
bution is marginal. In this regard, it must be stressed
that the “real” scenario (2) that represents the imaging
performed at our institution entails higher positioning
uncertainty than those scenarios with daily IGRT, so
that dose deviations arising from positioning errors
come into effect. Therefore, although this scenario in-
volves only little additional imaging dose and hence a
minor effect of IGRT dose on plan quality, the pos-
sible positioning errors themselves may compromise
plan quality.
The trade of between imaging dose and setup errors is
highly relevant and should be considered in future studies.
In the present work, the setup accuracy for the three sce-
narios with daily imaging can be considered identical and
optimal, so positioning errors can be neglected in the ana-
lysis for these plans and the three daily imaging scenarios
can be directly compared based on the imaging dose. How-
ever, for the non-daily scenario (the realistic case), statistical
setup errors can be expected to have remained present on
the days without imaging, leading to some degradation of
plan quality. Therefore, this plan cannot directly be
compared with the daily imaging scenarios. Similarly,
the original plan without imaging does certainly not
correspond to the dose distribution that would be expected
if no imaging was ever performed. Importantly, we do not
mean to suggest this scenario (no imaging) as a possible
alternative. Rather, this scenario should provide the
baseline against which the scenarios including imaging
should be compared. This should sensitize us to the fact
that the usual way of accepting a plan for treatment –
which is generally without any inclusion of imaging dose –
might not show any infringement of DVH constraints that
might be created by the additional imaging dose.
If daily IGRT is desired, a suitable scenario must be
chosen depending on the available imaging techniques.
For daily kV-CBCT, the additional dose contribution has
only minor impact on plan quality and NTCP. Regarding
the additional dose several studies and our own mea-
surements have found skin doses for kV imaging the
range of 1–3 cGy per image [32]. While this is not negli-
gible, the influence on plan quality is very small and can
be justified by the improvement in set-up accuracy. This
scenario is hence most desirable, since it combines low-
est concomitant dose with best image quality (soft-tissue
contrast). This offers the possibility of performing image
registration based on soft tissues rather than bony struc-
tures, so that motion of the prostate, bladder and rectum
relative to the bony landmarks and relative to each other
can be compensated for. Where this is available, this sce-
nario can be integrated into the clinical routine without
further difficulty.
However, since not every institution is equipped with a
kV-modality, we considered two alternative scenarios.
Daily IBL-CBCT results in a concomitant dose of up to
two additional fraction doses. Due to this additional
dose, the DVH constraints leading to plan acceptability
are no longer met for many cases (70 deviations from
the acceptance criteria of the original plan). Moreover,
high dose regions are induced in the PTV. The NTCP is
increased by up to 6% (proctitis grades 1 and 2: scenario
1: 35.88%, scenario 4: 41.34%). Although these are only
model values, a possible clinical relevance of the change
in dose should be kept in mind. We must stress that the
IBL technique has been marketed in some cases as “kV-
like”, which might leave the impression that it can be
employed as frequently as a “real” kV modality. As our
results demonstrate, this is not the case and the IBL,
while improving image quality and dose when compared
to 6 MV, is still an MV-photon beam and should be
employed with discretion.
Finally, unavailability of a kV technique does not
necessarily mean that daily IGRT must be abandoned.
As shown for the TBL, a scenario with daily axial images
and interspersed MV-CBCT can be designed so that plan
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quality is scarcely compromised. Depending on the fre-
quency of CBCT, the planning criteria can be met in most
cases, and the simulated effect on NTCP is minor. If IBL
is available, a similar scenario could be adopted, with a
further reduction in dose.
All scenarios relying on MV imaging (TBL or IBL) suffer
from the draw-back that soft tissues can hardly be dis-
cerned, even in CBCT images. Therefore, image fusion and
set-up corrections will primarily rely on bony structures.
This will be incapable of showing real prostate motion
within the body and different positions and size of bladder
and rectum. Therefore, larger safety margins will need to
be applied in PTV delineation and treatment planning.
When this is kept in mind, however, daily imaging can be
performed with these techniques. Furthermore, since this
relies on bony structures, the information loss in applying
axial planar imaging rather than CBCT is not as marked.
Using exclusively kV, an image fusion on soft tissue would
be possible leading to advantages in positioning precision.
Moreover the use of gold markers would be a good solu-
tion for the prostate. However, as this work primarily deals
with the additional imaging dose without taking into ac-
count potential setup errors, we assume that the imaging
modalities are able to control and correct setup errors in
the same way.
If daily volumetric imaging is desired in the absence of
a kV modality, a possibility is to include the additional
imaging dose in treatment planning. Including the planned
imaging dose in the treatment plan would give a realistic
approximation of the total dose and allow to optimize the
treatment in such a way that PTV hot-spots and exceeding
exposure of OARs can be avoided.
In this study, dose calculation accuracy for the MV
beams is comparable to standard requirements for commis-
sioned treatment beams; for the kV energy, the accuracy is
reduced since the dose calculation algorithms are optimized
for the energy range dominated by Compton scattering.
For the low energy photons where the photo effect comes
into play, deviations from the measurements at beam
commissioning were mostly below 10%, but could reach up
to 30% in the close vicinity to bony structures [24]. This
might slightly affect the doses at the femoral heads, but
should introduce only minor errors in the results for the
bladder and rectum.
In addition to the aspects of imaging dose and posi-
tioning accuracy, the time required for imaging plays an
important role in the clinical context. In principle, the
additional time amount for the different imaging modal-
ities is irrespective of the used energy, so that 6 MV and 1
MV imaging is identical from the point of view of imaging
time. In both cases, the flat panel needs to be deployed
opposite to the collimator (about 15 s). For kV imaging,
both a flat panel and the X-ray tube must be rotated into
the beam line (about 25 s). After deployment, performing
volumetric imaging requires more time than recording
two planar images. CBCTs with a full gantry rotation of
360° take about one minute and 30 s, while the two planar
projections including gantry movement can be taken in
less than one minute. However, the most time-consuming
part in IGRT is the merging and adaption of the verifica-
tion images with the images of the planning CT, in par-
ticular the selection of the planning CT images or digitally
reconstructed radiographs from the database. After this,
the auto-fusion algorithm runs in about 50 s for CBCTs. If
manual intervention is required, the time for image fusion
can be longer.
Conclusion
As modern radiation therapy offers the possibility for
steeper dose gradients leading to smaller safety margins,
it is essential to perform setup verification images regu-
larly. To evaluate the influence of different IGRT proto-
cols on plan quality, several clinically relevant scenarios
were simulated for a collective of 50 prostate cancer
patients. Daily kV-CBCT has smallest influence on plan
quality and is commendable for the clinical routine. If
no kV-modality is available, daily MV-CBCT – even the
nominal 1 MV image beam line – should not be used
without keeping in mind and possibly adjusting for the
additional imaging dose. A daily IGRT scenario with mostly
planar axial images and intermittent CBCT might be pre-
ferred. For these recommended scenarios, the model results
in less than 1% increase in NTCP.
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